Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Abstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient eliminat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-03-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-022-00947-7 |
| _version_ | 1811332198592151552 |
|---|---|
| author | Zhiwen Fu Shijun Li Sifei Han Chen Shi Yu Zhang |
| author_facet | Zhiwen Fu Shijun Li Sifei Han Chen Shi Yu Zhang |
| author_sort | Zhiwen Fu |
| collection | DOAJ |
| description | Abstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer drugs, known as “biological missiles”, is leading a new era of targeted cancer therapy. Herein, we conducted a review of the history and general mechanism of action of ADCs, and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. Moreover, we also reviewed the approved ADCs and other promising candidates in phase-3 clinical trials and discuss the current challenges and future perspectives for the development of next generations, which provide insights for the research and development of novel cancer therapeutics using ADCs. |
| first_indexed | 2024-04-13T16:32:18Z |
| format | Article |
| id | doaj.art-52618ef9d1cd472b9f890b76284fc5cb |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-04-13T16:32:18Z |
| publishDate | 2022-03-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-52618ef9d1cd472b9f890b76284fc5cb2022-12-22T02:39:31ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352022-03-017112510.1038/s41392-022-00947-7Antibody drug conjugate: the “biological missile” for targeted cancer therapyZhiwen Fu0Shijun Li1Sifei Han2Chen Shi3Yu Zhang4Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash UniversityDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer drugs, known as “biological missiles”, is leading a new era of targeted cancer therapy. Herein, we conducted a review of the history and general mechanism of action of ADCs, and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. Moreover, we also reviewed the approved ADCs and other promising candidates in phase-3 clinical trials and discuss the current challenges and future perspectives for the development of next generations, which provide insights for the research and development of novel cancer therapeutics using ADCs.https://doi.org/10.1038/s41392-022-00947-7 |
| spellingShingle | Zhiwen Fu Shijun Li Sifei Han Chen Shi Yu Zhang Antibody drug conjugate: the “biological missile” for targeted cancer therapy Signal Transduction and Targeted Therapy |
| title | Antibody drug conjugate: the “biological missile” for targeted cancer therapy |
| title_full | Antibody drug conjugate: the “biological missile” for targeted cancer therapy |
| title_fullStr | Antibody drug conjugate: the “biological missile” for targeted cancer therapy |
| title_full_unstemmed | Antibody drug conjugate: the “biological missile” for targeted cancer therapy |
| title_short | Antibody drug conjugate: the “biological missile” for targeted cancer therapy |
| title_sort | antibody drug conjugate the biological missile for targeted cancer therapy |
| url | https://doi.org/10.1038/s41392-022-00947-7 |
| work_keys_str_mv | AT zhiwenfu antibodydrugconjugatethebiologicalmissilefortargetedcancertherapy AT shijunli antibodydrugconjugatethebiologicalmissilefortargetedcancertherapy AT sifeihan antibodydrugconjugatethebiologicalmissilefortargetedcancertherapy AT chenshi antibodydrugconjugatethebiologicalmissilefortargetedcancertherapy AT yuzhang antibodydrugconjugatethebiologicalmissilefortargetedcancertherapy |